Key result
Recent advances in norovirus research, including successful cell culture systems and VLP-based vaccine candidates, offer promising pathways for future therapeutics and prevention.
Recent advances in norovirus cultivation and immunology are paving the way for the development of effective vaccines and antiviral therapeutics.
Advances remain preclinical; leaves open clinical translation pending human efficacy trials.
Norovirus (NoV) infections are an important cause of epidemic and sporadic viral gastroenteritis and a major cause of foodborne and waterborne outbreaks. NoV is characterized by genetic diversity, frequent mutations, and stability in a wide range of external environmental conditions. In recent years, a number of major advances that could overcome technical barriers have been made. The complex mechanisms of NoV pathogenesis and persistent infection involving interactions between the virus and the host immune system are being delineated. Human histo-blood group antigens, receptors for NoV attachment, play an important role in infection, which makes this interaction a critical target for the development of anti-NoV drugs. A number of vaccine candidates, chiefly based on virus-like particles, have entered phase 2 clinical development, and increasing efforts are being made to develop antiviral drugs. This review presents the current understanding of NoV immunology, epidemiology, therapeutic options, and vaccine development.
No takes yet. Share an insight, caveat, or question.
Han et al. (2017) conducted a review in Norovirus infection. Norovirus therapeutics and vaccines was evaluated. Recent advances in norovirus research, including successful cell culture systems and VLP-based vaccine candidates, offer promising pathways for future therapeutics and prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: